<DOC>
	<DOCNO>NCT02060058</DOCNO>
	<brief_summary>The aim study explore efficacy safety boceprevir -based triple therapy rescue HCV genotype 1 ( HCV GT1 ) /HBV dually infected patient refractory previous peginterferon ( PEG-IFN ) plus ribavirin ( RBV ) combination therapy .</brief_summary>
	<brief_title>Boceprevir-based Therapy Rescue HCV Genotype 1/HBV Infected Patients Refractory Combination Therapy</brief_title>
	<detailed_description>Liver disease , especially viral hepatitis , important public health issue , frequent lead liver cirrhosis , hepatocellular carcinoma ( HCC ) liver-related death . Around 340 400 million person infected hepatitis B virus ( HBV ) 130 210 million person infected hepatitis C virus ( HCV ) worldwide , In Taiwan , prevalence HBV infection 15-20 % , prevalence HCV infection 2-5 % general population . Moreover , HCV-hyperendemic area southern Taiwan anti-HCV prevalence rate high 30-40 % . HBV/HCV dual infection uncommon HBV epidemic area , Southeastern Asia , prevalence rate 1.1 % southern Taiwan . Recent study show risk HCC incidence even high among HBV/HCV co-infected person HBV HCV mono-infection , indicate importance disease control clinical setting . The PEG-IFN/RBV effective treatment HCV-dominant , treatment-naïve patient HCV/HBV dual infection . For treatment-naive HCV genotype 1 ( HCV GT1 ) /HBV co-infected patient , 48 week peginterferon ( PEG-IFN ) plus ribavirin ( RBV ) could achieve HCV sustain virological response ( SVR ) rate 72 % , comparable 77 % patient HCV GT1 monoinfection . For treatment-naive HCV GT2 GT3 /HBV co-infected patient , 24 week PEG-IFN plus RBV could achieve HCV SVR rate 83 % , comparable 84 % patient HCV GT2/3 monoinfection . Furthermore , PEG-IFN plus RBV combination therapy could enhance seroclearance hepatitis B surface antigen ( HBsAg ) HBsAg loss rate upto 11 % . Nevertheless , 30 % HCV GT1/HBV 20 % HCV GT2 3/HBV co-infected patient refractory current PEG-IFN/RBV combination therapy , remain high risk HCC liver-related death . Boceprevir oral antiviral drug , NS3/4A protease inhibitor . Boceprevir approve treat HCV GT1 infection Food Drug Administration ( FDA ) 11 May 2011 . For HCV GT1 mono-infected patient refractory previous PEG-IFN plus RBV combination therapy , becoprevir combine PEG-IFN/RBV triple therapy improve treatment efficacy . The SVR rate becoprevir-based triple therapy 3 time compare patient receive PEG-IFN RBV dual therapy [ 14 ] .The investigator , therefore , hypothesize boceprevir plus PEG-IFN/RBV effective treating HCV GT1/HBV dually infect patient refractory previous PEG-IFN/RBV combination therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Patient must 20 year old 2 . Patient must HCV GT1 infection combine HBV infection . 3 . Patients must serum HCV RNA detectable , antiHCV positive , HBsAg positive HBeAg negative . 4 . Patient previously fail treatment PEGIFNα 2a 2b/RBV minimum 12 week treatment . 5 . Patient must compensate liver disease consistent CHC and/or CHB , etiology . Note : patient cirrhosis liver image study ( e.g . ultrasound , CT scan MRI ) within precede 6 month show evidence hepatocellular carcinoma . 6 . Patient meet requirement none contraindication treatment PEGIFN alpha2b/RBV boceprevir define label PEGIFN/RBV use combination boceprevir . 7 . Patient able willing provide sign informed consent ( prepared administer physician ) require local country requirement . 1 . Mixed genotype include HCV genotype genotype 1 . 2 . Patient receive boceprevir , narlaprevir , telaprevir , HCV protease inhibitor treatment . 3 . Patient evidence decompensated liver disease include limited , history presence clinical ascites , bleed varix , hepatic encephalopathy . 4 . Patient meet follow exclusionary hematologic biochemical criterion ( documentation require ) Hemoglobin &lt; 12 gm/dL female &lt; 13 gm/dL male Neutrophils &lt; 1500/mm3 Platelets &lt; 100,000/mm3 5 . Patient organ transplant cornea hair . 6 . Patient coinfected human immunodeficiency virus ( HIV ) 7 . Patient require anticipated require follow prohibited medication : midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative 8 . Patient clinical diagnosis evidence substance abuse involve alcohol , intravenous drug , inhalational psychotropics , narcotic , cocaine prescription overthecounter drug . 9 . Patient previously demonstrate clinically significant hypersensitivity contraindication component boceprevir formulation . This drug contain lactose . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption take medicine . 10 . Serious illness , include malignancy , active coronary artery disease cardiac dysfunction within 24 week prior study entry , opinion site investigator may preclude completion treatment regimen . 11 . Major hemoglobinopathy ( e.g. , thalassemia major ) , coagulopathy cause tendency hemolysis bleeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>hepatitis C virus</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>boceprevir</keyword>
	<keyword>null responder</keyword>
	<keyword>partial responder</keyword>
	<keyword>relapser</keyword>
</DOC>